Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Sep 16;5(1):13.
doi: 10.1186/1465-9921-5-13.

Safety assessment of inhaled xylitol in mice and healthy volunteers

Affiliations
Clinical Trial

Safety assessment of inhaled xylitol in mice and healthy volunteers

Lakshmi Durairaj et al. Respir Res. .

Abstract

Background: Xylitol is a 5-carbon sugar that can lower the airway surface salt concentration, thus enhancing innate immunity. We tested the safety and tolerability of aerosolized iso-osmotic xylitol in mice and human volunteers.

Methods: This was a prospective cohort study of C57Bl/6 mice in an animal laboratory and healthy human volunteers at the clinical research center of a university hospital. Mice underwent a baseline methacholine challenge, exposure to either aerosolized saline or xylitol (5% solution) for 150 minutes and then a follow-up methacholine challenge. The saline and xylitol exposures were repeated after eosinophilic airway inflammation was induced by sensitization and inhalational challenge to ovalbumin. Normal human volunteers underwent exposures to aerosolized saline (10 ml) and xylitol, with spirometry performed at baseline and after inhalation of 1, 5, and 10 ml. Serum osmolarity and electrolytes were measured at baseline and after the last exposure. A respiratory symptom questionnaire was administered at baseline, after the last exposure, and five days after exposure. In another group of normal volunteers, bronchoalveolar lavage (BAL) was done 20 minutes and 3 hours after aerosolized xylitol exposure for levels of inflammatory markers.

Results: In naive mice, methacholine responsiveness was unchanged after exposures to xylitol compared to inhaled saline (p = 0.49). There was no significant increase in Penh in antigen-challenged mice after xylitol exposure (p = 0.38). There was no change in airway cellular response after xylitol exposure in naive and antigen-challenged mice. In normal volunteers, there was no change in FEV1 after xylitol exposures compared with baseline as well as normal saline exposure (p = 0.19). Safety laboratory values were also unchanged. The only adverse effect reported was stuffy nose by half of the subjects during the 10 ml xylitol exposure, which promptly resolved after exposure completion. BAL cytokine levels were below the detection limits after xylitol exposure in normal volunteers.

Conclusions: Inhalation of aerosolized iso-osmotic xylitol was well-tolerated by naive and atopic mice, and by healthy human volunteers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of saline and xylitol exposure on methacholine responsiveness in naïve mice (n = 6/group). Panel A reflects methacholine responsiveness before and after saline exposure. Panel B reflects methacholine responsiveness before and after xylitol exposure. Error bars = SD. P-values of all comparisons are non-significant.
Figure 2
Figure 2
Effect of saline vs. xylitol exposure on Penh of naïve C57BL/6 mice (n = 6). The figure shows mean Penh values for mice exposed to saline (circles) and xylitol (squares). Errors bars = SD. p = 0.21.
Figure 3
Figure 3
Invasive airway resistance measurement in response to methacholine challenge in naïve and ova-challenged C57BL/6 mice (n = 2/group) using Flexivent system. The figure shows mean airway resistance for naïve mice (squares) ova-challenged mice (triangles).
Figure 4
Figure 4
Effect of exposure to nebulized saline and xylitol on spirometry in normal volunteers (n = 10). The figure shows mean FEV1 (% predicted) at baseline, after exposure to saline (10 ml), and xylitol (1, 5, and 10 ml). Errors bars = SD. p = 0.19.

References

    1. Travis SM, Singh PK, Welsh MJ. Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol. 2001;13:89–95. doi: 10.1016/S0952-7915(00)00187-4. - DOI - PubMed
    1. Lehrer RI, Ganz T. Antimicrobial peptides in mammalian and insect host defense. Curr Opin Immunol. 1999;11:23–27. doi: 10.1016/S0952-7915(99)80005-3. - DOI - PubMed
    1. Huttner KM, Bevins CL. Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res. 1999;45:785–794. - PubMed
    1. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest. 1999;103:303–307. - PMC - PubMed
    1. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic inlung that is inactivated in cystic fibrosis. Cell. 1997;88:553–560. doi: 10.1016/S0092-8674(00)81895-4. - DOI - PubMed

Publication types